Beam Therapeutics (BEAM) Projected to Post Quarterly Earnings on Tuesday

Beam Therapeutics (NASDAQ:BEAM) is expected to post its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Beam Therapeutics to post earnings of ($1.13) per share and revenue of $13.2150 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 7:00 AM ET.

Beam Therapeutics Price Performance

Shares of BEAM stock opened at $27.59 on Friday. The firm has a fifty day moving average of $28.60 and a two-hundred day moving average of $24.77. The firm has a market cap of $2.80 billion, a P/E ratio of -6.23 and a beta of 2.12. Beam Therapeutics has a 1-year low of $13.52 and a 1-year high of $36.44.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on BEAM shares. Sanford C. Bernstein lifted their price target on Beam Therapeutics from $37.00 to $41.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 20th. UBS Group began coverage on Beam Therapeutics in a research report on Wednesday, January 7th. They issued a “neutral” rating and a $28.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beam Therapeutics in a report on Wednesday, January 21st. Benchmark restated a “speculative buy” rating on shares of Beam Therapeutics in a research note on Monday, November 17th. Finally, Wall Street Zen cut Beam Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, February 8th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Beam Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $45.69.

Insider Activity

In other news, insider Christine Bellon sold 18,629 shares of Beam Therapeutics stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $34.61, for a total value of $644,749.69. Following the transaction, the insider owned 97,038 shares of the company’s stock, valued at $3,358,485.18. The trade was a 16.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 3.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Beam Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Larson Financial Group LLC grew its position in Beam Therapeutics by 4,370.5% during the 3rd quarter. Larson Financial Group LLC now owns 1,967 shares of the company’s stock worth $48,000 after purchasing an additional 1,923 shares in the last quarter. Kestra Advisory Services LLC acquired a new stake in shares of Beam Therapeutics during the 4th quarter valued at about $59,000. Van ECK Associates Corp increased its holdings in Beam Therapeutics by 48.7% in the third quarter. Van ECK Associates Corp now owns 2,158 shares of the company’s stock worth $52,000 after buying an additional 707 shares during the last quarter. IFC & Insurance Marketing Inc. acquired a new position in Beam Therapeutics in the fourth quarter worth approximately $69,000. Finally, CIBC Private Wealth Group LLC raised its position in Beam Therapeutics by 46.6% during the fourth quarter. CIBC Private Wealth Group LLC now owns 3,144 shares of the company’s stock valued at $87,000 after acquiring an additional 1,000 shares in the last quarter. Institutional investors and hedge funds own 99.68% of the company’s stock.

About Beam Therapeutics

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.